Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 270

1.

Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study.

Di Giuda D, Camardese G, Bentivoglio AR, Cocciolillo F, Guidubaldi A, Pucci L, Bruno I, Janiri L, Giordano A, Fasano A.

Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1937-48. doi: 10.1007/s00259-012-2232-7. Epub 2012 Sep 14.

PMID:
22976499
2.

Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT.

Varrone A, Sansone V, Pellecchia MT, Amboni M, Salvatore E, De Michele G, Filla A, Barone P, Pappatà S, Salvatore M.

Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1343-9. doi: 10.1007/s00259-008-0729-x. Epub 2008 Feb 19.

PMID:
18283454
3.

Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients.

Erro R, Pappatà S, Amboni M, Vicidomini C, Longo K, Santangelo G, Picillo M, Vitale C, Moccia M, Giordano F, Brunetti A, Pellecchia MT, Salvatore M, Barone P.

Parkinsonism Relat Disord. 2012 Nov;18(9):1034-8. doi: 10.1016/j.parkreldis.2012.05.022. Epub 2012 Jul 11.

PMID:
22789824
4.

Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.

Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, Stoof JC, Wolters EC.

J Nucl Med. 1998 Jul;39(7):1143-8.

5.

[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.

Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, Wolters EC, van Royen EA.

J Neurol Neurosurg Psychiatry. 1997 Feb;62(2):133-40.

6.

Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report.

Di Giuda D, Calcagni ML, Totaro M, Cocciolillo F, Piano C, Soleti F, Fasano A, Cioni B, Bentivoglio AR, Giordano A.

Nucl Med Commun. 2012 Sep;33(9):933-40. doi: 10.1097/MNM.0b013e3283561810.

PMID:
22735298
7.

Comment on Di Giuda et al.: Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study.

Erro R, Pappatà S, Barone P, Pellecchia MT.

Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):636-7. doi: 10.1007/s00259-012-2300-z. Epub 2012 Dec 7. No abstract available.

PMID:
23224741
8.

123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms.

Filippi L, Manni C, Pierantozzi M, Brusa L, Danieli R, Stanzione P, Schillaci O.

Nucl Med Commun. 2005 May;26(5):421-6.

PMID:
15838424
9.

Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.

Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, Janssen AG, Stoof JC, van Royen EA.

J Nucl Med. 1998 Nov;39(11):1879-84.

10.

Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease.

Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, Kleiner-Fisman G, Duda JE, Stern MB, Mozley D, Katz IR.

J Nucl Med. 2005 Feb;46(2):227-32.

11.

Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT study: reply to comment by Erro et al.

Di Giuda D, Camardese G, Cocciolillo F, Fasano A.

Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):638-9. doi: 10.1007/s00259-012-2303-9. Epub 2012 Dec 7. No abstract available.

PMID:
23224742
12.

Clinical impact of correlative [123I]-FP-CIT brain imaging and neurological findings in suspect Parkinson's disease.

Covelli EM, Brunetti A, Di Lauro A, Sullo P, Mazzarella G, Tedeschi E, Belfiore G.

Radiol Med. 2004 Oct;108(4):417-25. English, Italian.

PMID:
15525895
13.

Dopamine transporter imaging (123)I-FP-CIT (DaTSCAN) SPET in differential diagnosis of dopa-responsive dystonia and young-onset Parkinson's disease.

Brajkovic LD, Svetel MV, Kostic VS, Sobic-Saranovic DP, Pavlovic SV, Artiko VM, Obradovic VB.

Hell J Nucl Med. 2012 May-Aug;15(2):134-8.

PMID:
22833860
14.
15.

Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake.

Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG.

Mov Disord. 2000 Jul;15(4):692-8.

PMID:
10928580
16.

Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson's disease.

Kaasinen V, Kinos M, Joutsa J, Seppänen M, Noponen T.

Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1931-7. doi: 10.1007/s00259-014-2796-5. Epub 2014 May 28.

PMID:
24867256
17.

The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases.

Sixel-Döring F, Liepe K, Mollenhauer B, Trautmann E, Trenkwalder C.

J Neurol. 2011 Dec;258(12):2147-54. doi: 10.1007/s00415-011-6076-z. Epub 2011 May 6.

PMID:
21547379
18.

Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study.

Roselli F, Pisciotta NM, Perneczky R, Pennelli M, Aniello MS, De Caro MF, Ferrannini E, Tartaglione B, Defazio G, Rubini G, Livrea P.

Mov Disord. 2009 Oct 30;24(14):2097-103. doi: 10.1002/mds.22702.

PMID:
19705471
19.

Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls.

Eshuis SA, Jager PL, Maguire RP, Jonkman S, Dierckx RA, Leenders KL.

Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):454-62. doi: 10.1007/s00259-008-0989-5. Epub 2008 Nov 27.

PMID:
19037637
Items per page

Supplemental Content

Write to the Help Desk